Research News
View articles by month and year
-
Aromatase Inhibitors Seem Less Effective in Obese Women
A small study found that while obese women diagnosed with early-stage, hormone-receptor-positive breast cancer who took Arimidex and Femara had lower estrogen levels than before they started treatment, their estrogen levels were still more than double those of women at a healthy weight.
-
Aromasin Reduces Risk But Weakens Bones
Research shows that Aromasin is good at lowering breast cancer risk in high-risk postmenopausal women, but weakens bones.
-
Arimidex-Faslodex Combo Improves Survival in Metastatic Breast Cancer
A study has found that postmenopausal women diagnosed with hormone-receptor-positive metastatic breast cancer and treated with a combination of Arimidex and Faslodex as the first treatment for metastatic disease lived 6 months longer than women treated only with Arimidex.
-
Fracture Risk in Younger Women Being Treated for Breast Cancer Higher Than Thought
A study found that about 16% of premenopausal women treated for early-stage breast cancer broke a bone during treatment or in the years after treatment; this rate was 60% higher than expected.
-
Femara Offers More Benefits Than Tamoxifen After Breast Cancer Surgery
New results boost evidence that postmenopausal women get more benefits from 5 years of Femara compared to 5 years of tamoxifen after surgery for early-stage, hormone-receptor-positive breast cancer.
-
Hormonal Therapy Before Surgery May Be Good Treatment for Postmenopausal Women with Hormone-Receptor-Positive, Locally Advanced Disease
Research suggests that hormonal therapy before surgery may be a good alternative to chemotherapy before surgery for postmenopausal women diagnosed with hormone-receptor-positive breast cancer.
-
Prolia Approved by FDA to Treat Bone Loss in Women Taking Aromatase Inhibitor
The osteoporosis drug denosumab (Prolia) is now FDA-approved to treat bone loss in women taking aromatase inhibitors.
-
Most Women with Early-Stage Breast Cancer Benefit from Treatments After Surgery
Research suggests that that most women diagnosed with early-stage breast cancer are likely to benefit from chemotherapy, hormonal therapy, and/or targeted therapy after surgery.
-
Is Switching Hormonal Therapies Better Than Taking Only One?
Research suggests that taking tamoxifen for 2 to 3 years and then switching to an aromatase inhibitor might be better than taking only tamoxifen or only an aromatase inhibitor for 5 years to reduce recurrence risk and improve overall survival.
-
Tamoxifen Reduces Recurrence Risk for More Than 10 Years
Research has confirmed that tamoxifen reduces breast cancer recurrence risk during the standard 5 years of treatment and that recurrence risk stays lower during the next 5 years after tamoxifen treatment ends.
